The **HAINS Mycobacterium Tuberculosis First Line Drug Resistance Profile** is a molecular diagnostic test designed to detect genetic mutations in *Mycobacterium tuberculosis* that confer resistance to first-line anti-TB drugs such as rifampicin and isoniazid. Using line probe assay technology, this test provides rapid and accurate identification of drug-resistant strains directly from patient samples. It is performed to guide clinicians in selecting effective treatment regimens, ensuring timely management of tuberculosis, and preventing the spread of resistant infections.
Doctors use it to identify drug-resistant TB strains quickly, ensuring patients receive effective treatment and preventing spread of resistant infections.
It indicates the TB bacteria carry mutations making them resistant to specific first-line drugs, requiring alternative treatment regimens.
It suggests no detectable resistance mutations, meaning standard first-line TB drugs may be effective.
Patients with suspected TB, especially those not responding to standard treatment or at risk of drug resistance, should undergo this test.
Yes, it identifies resistance to rifampicin and isoniazid, the two key drugs defining multidrug-resistant TB.
No, it is diagnostic. Clinical monitoring and follow-up cultures track treatment response.
...
Didn't recieved OTP Yet? Resend OTP